Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products

Holló, Gábor; Vuorinen, Jouni; Tuominen, Juhani; Huttunen, Teppo; Ropo, Auli; Pfeiffer, Norbert

doi:10.1007/s12325-014-0151-7

Cited by 39 publications

(38 citation statements)

References 39 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At the final visit, individual IOPs were lower compared with baseline in 89.5% eyes, unchanged in 5.1% eyes and higher in 5.4% eyes. Interestingly, the IOP response seems to be dependent on the baseline IOP levels, which confirms earlier results: eyes with higher baseline IOP levels showed a higher absolute response and percentage IOP decrease as compared to eyes with lower baseline IOP levels 20. This result was found for patients with prior medical treatment and also for the subgroup of treatment-naïve patients.…”

Section: Discussionsupporting

confidence: 88%

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study

Pillunat

Erb²,

Ropo

et al. 2017

OPTH

Self Cite

View full text Add to dashboard Cite

BackgroundEfficacy, tolerability and safety of the novel preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% (Taptiqom®) were investigated in an observational study in Germany.ObjectiveTo assess efficacy, tolerability and safety of the preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% in a real-life setting.MethodsIntraocular pressure (IOP) was recorded for each eye at baseline (any previous therapy or untreated) and 4–16 weeks after changing medical treatment to or initiating treatment with the preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5%. Change in IOP was evaluated over the study period for all patients and for specific pretreatment subgroups. Clinical signs such as conjunctival hyperemia and lid-parallel conjunctival folds (LIPCOF) were recorded using standardized comparative photographs. Corneal staining, subjective symptoms and local comfort were measured using a four-step scale. All adverse events were recorded.ResultsAmong 1,157 patients enrolled, 1,075 patients were treated with the preservative-free fixed combination as the only medication at the final visit. Medical treatment was initiated in 741 patients because of an insufficient IOP-lowering effect of the prior medication. In 343 patients, medication was changed because of tolerability issues. The preservative-free fixed combination lowered IOP significantly in the subgroup of naïve patients, all subgroups with prior monotherapy and patients with prior fixed combinations: naïve patients: −8.9 mmHg, alpha- 2-agonists: −6.4 mmHg, beta-blockers: −5.7 mmHg, carbonic anhydrase inhibitors: −5.2 mmHg, prostaglandins: −4.7 mmHg, fixed-combination prostaglandins/timolol: −2.4 mmHg. At the final visit, clinical signs and subjective symptoms were improved in patients with prior medical therapy. Local comfort was rated as “very good” or “good” by 89.1% of patients at the final visit. Only few adverse events occurred during the treatment period.ConclusionThe preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% was effective, well tolerated and showed a good safety profile.

show abstract

Section: Discussionsupporting

confidence: 88%

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study

Pillunat

Erb²,

Ropo

et al. 2017

OPTH

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although comparisons across studies should be made with caution, data from the two phase III studies compare favourably with those reported for preservative-containing or -free fixed-dose combination therapies with a prostaglandin analogue and timolol (bimatoprost/timolol, latanoprost/timolol and travoprost/timolol) [23]. Tafluprost/timolol was well tolerated in clinical studies in adults with open-angle glaucoma or ocular hypertension (Sect.…”

Section: Current Status Of Tafluprost/timolol In Openangle Glaucoma Omentioning

confidence: 72%

Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension

Hoy

2015

Drugs

View full text Add to dashboard Cite

A once-daily preservative-free fixed combination ophthalmic solution containing tafluprost 0.0015 % and timolol 0.5 % (hereafter referred to as tafluprost/timolol) [Taptiqom(®)] has been developed to lower intraocular pressure (IOP) whilst avoiding damage to the ocular surface associated with preservatives such as benzalkonium chloride. Tafluprost/timolol is available in various EU countries for the reduction of IOP in adults with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical monotherapy with β-adrenergic receptor antagonists or prostaglandin analogues and require a combination therapy, and who would benefit from preservative-free eye drops. In two multinational, phase III studies, tafluprost/timolol was superior to monotherapy with either preservative-free tafluprost 0.0015 % once daily or preservative-free timolol 0.5 % twice daily, and noninferior to concomitant therapy with preservative-free tafluprost 0.0015 % once daily plus preservative-free timolol 0.5 % twice daily in lowering IOP in adults with open-angle glaucoma or ocular hypertension. Tafluprost/timolol was well tolerated in these studies, with a tolerability profile consistent with that of its individual components and with no new adverse reactions observed. Thus, preservative-free fixed combination tafluprost/timolol is an effective treatment option for the reduction of IOP in adults with open-angle glaucoma or ocular hypertension, providing a useful alternative for those patients who would benefit from preservative-free eye drops.

show abstract

“…In a systematic review21 comparing the four fixed dose timolol/PGA combinations, the IOP reduction with preservative-free tafluprost/timolol combination (from the two RCTs described above27,28) was similar to that of other PGA/timolol fixed combination products in previous studies (and heavily dependent on the baseline IOP). Hyperaemia occurred in 1.8–8.5% with latanoprost/timolol, 6.4–8.0% with tafluprost/timolol, 10.8–15.0% with travoprost/timolol and 19–26% with bimatoprost/timolol (no p values reported) 21.…”

Section: Drug Therapymentioning

confidence: 68%

“…Hyperaemia occurred in 1.8–8.5% with latanoprost/timolol, 6.4–8.0% with tafluprost/timolol, 10.8–15.0% with travoprost/timolol and 19–26% with bimatoprost/timolol (no p values reported) 21. Eye irritation occurred in 2.3–9.0% with latanoprost/timolol, 7.0–12.7% with tafluprost/timolol, 11.5–23.6% with travoprost/timolol and 8.5–23.8% with bimatoprost/timolol (no p values reported).…”

Section: Drug Therapymentioning

confidence: 97%

See 1 more Smart Citation

New drugs and preparations for open-angle glaucoma in adults

2015

DTB

View full text Add to dashboard Cite

Primary (or chronic) open-angle glaucoma (POAG or COAG) may be asymptomatic but causes progressive optic nerve damage with significant loss of visual field. Treatments aim to lower intraocular pressure (IOP) by reducing the production of aqueous humour and/or increasing its drainage. Here we update our previous articles to reflect new drugs, preservative-free preparations and fixed-dose drug combinations for POAG.

show abstract

Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products

Cited by 39 publications

References 39 publications

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study

Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension

New drugs and preparations for open-angle glaucoma in adults

Contact Info

Product

Resources

About